Back to top

crispr: Archive

Zacks Equity Research

EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce

Editas stock falls as it ends development of reni-cel for SCD and TDT following failed attempts to find a commercial partner. It plans to cut workforce by 65%.

EDITPositive Net Change CTMXPositive Net Change SPRONegative Net Change CSTLPositive Net Change